China · Delayed Price · Currency is CNY Daan Gene Statistics
Total Valuation
Daan Gene has a market cap or net worth of CNY 8.07 billion. The enterprise value is 6.96 billion.
| Market Cap | 8.07B |
| Enterprise Value | 6.96B |
Important Dates
The next confirmed earnings date is Monday, October 26, 2026.
| Earnings Date | Oct 26, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Daan Gene has 1.40 billion shares outstanding. The number of shares has decreased by -1.21% in one year.
| Current Share Class | 1.40B |
| Shares Outstanding | 1.40B |
| Shares Change (YoY) | -1.21% |
| Shares Change (QoQ) | -9.21% |
| Owned by Insiders (%) | 2.02% |
| Owned by Institutions (%) | 5.72% |
| Float | 931.17M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 10.80 |
| PB Ratio | 1.11 |
| P/TBV Ratio | 1.22 |
| P/FCF Ratio | 37.40 |
| P/OCF Ratio | 22.68 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 9.32 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 32.25 |
Financial Position
The company has a current ratio of 2.96, with a Debt / Equity ratio of 0.01.
| Current Ratio | 2.96 |
| Quick Ratio | 2.43 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | 0.48 |
| Interest Coverage | -61.85 |
Financial Efficiency
Return on equity (ROE) is -9.41% and return on invested capital (ROIC) is -4.50%.
| Return on Equity (ROE) | -9.41% |
| Return on Assets (ROA) | -1.97% |
| Return on Invested Capital (ROIC) | -4.50% |
| Return on Capital Employed (ROCE) | -3.73% |
| Weighted Average Cost of Capital (WACC) | 6.69% |
| Revenue Per Employee | 495,959 |
| Profits Per Employee | -453,256 |
| Employee Count | 1,506 |
| Asset Turnover | 0.09 |
| Inventory Turnover | 3.91 |
Taxes
In the past 12 months, Daan Gene has paid 44.46 million in taxes.
| Income Tax | 44.46M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -8.59% in the last 52 weeks. The beta is 0.45, so Daan Gene's price volatility has been lower than the market average.
| Beta (5Y) | 0.45 |
| 52-Week Price Change | -8.59% |
| 50-Day Moving Average | 5.51 |
| 200-Day Moving Average | 5.92 |
| Relative Strength Index (RSI) | 60.05 |
| Average Volume (20 Days) | 17,840,254 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Daan Gene had revenue of CNY 746.91 million and -682.60 million in losses. Loss per share was -0.50.
| Revenue | 746.91M |
| Gross Profit | 99.72M |
| Operating Income | -274.36M |
| Pretax Income | -670.40M |
| Net Income | -682.60M |
| EBITDA | -48.47M |
| EBIT | -274.36M |
| Loss Per Share | -0.50 |
Balance Sheet
The company has 1.44 billion in cash and 103.70 million in debt, with a net cash position of 1.33 billion or 0.95 per share.
| Cash & Cash Equivalents | 1.44B |
| Total Debt | 103.70M |
| Net Cash | 1.33B |
| Net Cash Per Share | 0.95 |
| Equity (Book Value) | 7.24B |
| Book Value Per Share | 5.00 |
| Working Capital | 1.81B |
Cash Flow
In the last 12 months, operating cash flow was 355.82 million and capital expenditures -140.02 million, giving a free cash flow of 215.80 million.
| Operating Cash Flow | 355.82M |
| Capital Expenditures | -140.02M |
| Depreciation & Amortization | 225.89M |
| Net Borrowing | 7.90M |
| Free Cash Flow | 215.80M |
| FCF Per Share | 0.15 |
Margins
Gross margin is 13.35%, with operating and profit margins of -36.73% and -91.39%.
| Gross Margin | 13.35% |
| Operating Margin | -36.73% |
| Pretax Margin | -89.76% |
| Profit Margin | -91.39% |
| EBITDA Margin | -6.49% |
| EBIT Margin | -36.73% |
| FCF Margin | 28.89% |
Dividends & Yields
Daan Gene does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 1.21% |
| Shareholder Yield | 1.21% |
| Earnings Yield | -8.46% |
| FCF Yield | 2.67% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 19, 2021. It was a forward split with a ratio of 1.6.
| Last Split Date | May 19, 2021 |
| Split Type | Forward |
| Split Ratio | 1.6 |
Scores
Daan Gene has an Altman Z-Score of 6.23 and a Piotroski F-Score of 3.
| Altman Z-Score | 6.23 |
| Piotroski F-Score | 3 |